- Indication: Sjogren’s Syndrome
- Enrollment Status: Enrollment Open
- Protocol: HZNP-DAZ-301, HZNP-DAZ-301 HZNP-DAZ-304 “Oasis”
- Drug: Dazodalibep
- Sponsor: Horizon/Amgen
- Description:
- 301 Description: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
- 303 Description: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-Severe Symptom State
- 304 Description: A Multicenter, Long term, Randomized, Extension Study to Evaluate Safety and Tolerability of Dazodalibep in Subjects with Sjögren’s Syndrome (SS)
